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Abstract: The ability to generate inducible pluripotent stem cells (iPSCs) and the potential 
for their use in treatment of human disease is of immense interest. Autoimmune diseases, 
with their limited treatment choices are a potential target for the clinical application of 
stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune 
disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through 
immune-modulation of the disease process in vivo; and (iii) for the purposes of disease 
modeling in vitro. In this review, we will use examples of systemic, system-specific and 
organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of 
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autoimmune diseases and review the evidence of iPSC technology in auto-immunity  
to date. 
Keywords: inducible; pluripotent; stem cells; autoimmunity; therapy; lupus; diabetes; 
multiple sclerosis 
 
1. Introduction  
Pluripotent stem cells have the ability to differentiate into all three of the embryonic germ layers, 
endoderm, mesoderm, or ectoderm. While these pluripotent cells may be of embryonic origin, somatic 
cells can be induced into this pluripotency state by transient ectopic expression of defined groups of 
transcription factors, hence the term “inducible” pluripotent stem cells (iPSCs). The advantages of 
inducing pluripotency includes the potential generation of unlimited numbers of required cells, 
deriving cells from hard-to-source tissues, reproduction of disease models, bypassing the ethical 
concerns regarding the use of embryonic stem cells and importantly provide an autologous cell therapy 
strategy that removes the need for immune suppression drugs. 
2. Background 
Following the seminal paper by Takahashi and Yamanaka [1], which reported using appropriate 
transcription factors, Oct4, Sox2, Klf4, and c-Myc, mouse fibroblasts could be reprogrammed into a 
pluripotent state, it has been demonstrated in human somatic cells. Furthermore, other combinations of 
transcription factors are able to induce pluripotency in human somatic cells as well [1–5]. 
Autoimmune diseases affect individual organs or a combination of organs, including the kidneys, 
brain, bone marrow, joints, or skin, however, the pathogenesis of most autoimmune diseases remains, 
at best, only partially delineated. IPSC technology has the potential to provide key cellular subsets 
which, given to patients, may alter their disease course by providing pure replacement of lost cells, 
may limit damage through immune-modulation of the disease process in vivo, and may provide 
substrates for the purposes of disease modeling in vitro. In this review, systemic lupus erythematosus 
(SLE) is taken as a prototypical example of a systemic auto-immune disease, along with rheumatoid 
arthritis (RA); diabetes mellitus (DM) as an example of organ specific autoimmunity; and multiple 
sclerosis (MS) as an example of system-specific neurological autoimmunity, to demonstrate the 
promising future research potential towards translational medicine of iPSC-derived treatment in a 
range of different contexts within Clinical Immunology.  
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3. Disease Immunomodulation and Potential Cellular Components—SLE and RA as Examples 
The loss of tolerance to self is the fundamental basis of autoimmunity, with resultant aberrant 
immune responses of autoantibody formation and/or cellular immunity against self-tissue.  
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease. Usually 
affecting women of childbearing age, it is characterised by the production of multiple auto-antibodies 
directed against double-stranded DNA and other nuclear antigens, which are widely distributed 
throughout the body. The autoantibodies are produced by activated auto-reactive B cells following 
presentation of these self-antigens to self-reactive T cells. Along with autoantibody production are 
reduced populations of regulatory T cells (Tregs), reduced responses to regulation by these cells on 
effector T cells, immunological dysregulation and increased inflammation [6], immune complex 
formation and deposition, and end-organ damage, particularly if the disease affects the kidneys or 
central nervous system.  
Rheumatoid arthritis is a symmetrical, inflammatory disease of synovial joints which also manifests 
extra-articular pathology in about 40% of patients. Affecting other parts of the musculoskeletal system, 
as well as the skin, eye, lung, heart, kidney, and vascular and nervous system tissues, it is likely that 
the inflammatory processes driving the synovial inflammation are also responsible for these  
extra-articular manifestations. RA patients develop autoantibodies to post-translationally modified 
synovial or stress-related proteins, which results in the conversion of arginine residues into citrulline  
(a process known as citrullination). In genetically susceptible individuals, preferential binding of these 
citrullinated self-peptides to MHC molecules may enable presentation to peripheral T cells, allowing 
expansion of potentially self-reactive T-cell populations. At the same time, if there is no presentation 
centrally in the thymus, there is no deletion or negative selection of autoreactive T cell populations, 
which is a possible mechanism for loss of self-tolerance in RA.  
The mainstay of treatment, for both SLE and RA, is with immunosuppressive medications, 
however, true immunomodulation in the absence of toxicity is difficult to achieve.  
There are a number of important cell populations that impact on systemic autoimmune disease 
course in which iPSC technology could potentially assist to model their effects and ideally contribute 
to regaining self-tolerance, such as regulatory T cells (Tregs) and dendritic cells. Targeting of 
particular cell lineages, rather than their end products, is also likely to be beneficial in the treatment of 
other autoimmunity diseases.  
3.1. Regulatory T Cells (Tregs) 
Regulatory T cells (Tregs), have an important role in the state of equilibrium that is immune 
tolerance, and are, therefore, also known as tolerogenic T cells. Tregs are CD4, CD25, and Foxp3 
positive, and act to restrict the extent and duration of T cell mediated immune responses, and maintain 
peripheral tolerance by suppressing auto-reactive T cells that have escaped negative selection in the 
thymus. The mechanisms by which Tregs work continue to be discovered [7]. Most Tregs arise 
centrally in the thymus where cell lineage commitment is determined by T-cell receptor (TCR) 
specificity to self antigen. The transcription factor Foxp3 stabilises gene expression that specifies Treg 
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differentiation while other transcription factors, including c-Rel, links TCR engagement and Foxp3 
expression, within an appropriate cytokine and co-stimulatory molecule milieu, for Treg differentiation. 
In the periphery, Tregs can be induced following repeated antigen exposure [8] under the influence 
of TGF-beta, converting Foxp3 negative T cells into Foxp3 positive induced Tregs (iTregs). Hence, 
this replaces T effector populations with regulatory populations, converting harmful responses to 
beneficial regulatory responses. 
The list of potential defects in Tregs leading to autoimmune diseases are many (Table 1). 
Considering this extensive list, however, enables multiple potential targets for iPSC application and 
analysis of disease processes. 
Table 1. Potential defects in regulatory T cells in autoimmune diseases [9,10]. 
Imbalances in peripheral effector and regulatory T cells due to defects in  
thymic selection 
Genetic defects inducing failed Treg function or inadequate Treg activity 
Overwhelming of Treg responses due to epitope spreading in autoimmune diseases, 
Deficient IL-2 (required for Treg development) 
Low CD25 expression (hence reduction of IL-2 signalling)  
Defective conversion of naive T cells to adaptive Tregs (due to IL-10 or  
TGF-beta deficiency) 
APC maturation defects leading to altered T cell activation and altered development 
of tolerogenic phenotype 
Hyper-costimulation by APCs leading to pathogenic T cells rather than  
tolerogenic phenotype 
Aberrant cytokine milieu leading to Treg suppression  
The transfer of autologous Tregs to suppress immune responses has already been demonstrated 
experimentally in SLE and other autoimmune diseases such as diabetes mellitus [11,12]. Regulatory T 
cells are present at locations of inflammation (e.g., synovial fluid, mucosa) [13] though, if regulatory T 
cells are obtained from these sites, there may be inadvertent contamination of auto-reactive effector T 
cells, which could lead to unintended inflammatory consequences from therapeutic reinfusion of 
collected cells. Once isolated, it is technically challenging to induce these regulatory T cells to 
proliferate exogenously, which places limits on the application of harvested Tregs from patients for use 
in therapeutic treatments. 
The ability to instead induce functional Tregs rather than needing to collect them, has been 
demonstrated from iPSCs in vivo [14]. These cells produced the immunoregulatory cytokines TGF 
beta and IL-10, thus producing a population of presumably functional Tregs. In a promising find, both 
allogeneic and autologous transfers of these iPSC derived Tregs demonstrated clinical efficacy, by 
reducing disease incidence and clinical severity scores in collagen-induced arthritis (CIA), an inducible 
mouse model of RA. 
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3.2. Dendritic Cells 
Dendritic cells are highly proficient APCs that are potent in stimulating naive T cells during the 
primary immune response [15]. Numerous abnormalities in dendritic cells have been noted in patients 
with autoimmune diseases, including variations in cells proportions, differences in cytokine  
receptor expression particularly inhibitory receptors, and increased expression of costimulatory  
molecules [16,17].  
Conventional dendritic cells (cDCs, previously known as myeloid DCs) are extremely efficient 
APCs, expressing several Toll-like receptors (TLRs) on their surface and producing TNF-alpha, IL-1, 
IL-6, IL-12, and IL-10 upon stimulation. Under different stimuli, cDCs can demonstrate different 
tolerogenic phenotypes, inducing antigen-specific unresponsiveness in central and peripheral lymphoid 
organs, and, therefore, have a crucial role in the induction of immune tolerance [18]. These tolerogenic 
dendritic cells are characteristically able to induce proliferation of Tregs (which then modulate immune 
responses to self-antigens), and to induce anergy in auto-reactive effector T cells [18,19]. Depending on 
the stimuli applied to the cDCs, different tolerogenic phenotypes are demonstrated, with functional 
differences in the Treg responses that are elicited [10]. Thus, depending on the desired Treg outcome, 
there is potential to preferentially select these outcomes by altering the particular phenotype of the 
applied tolerogenic dendritic cell in disease immunotherapy.  
For example, Tregs can be induced in vivo by NFKB or CD40-deficient DCs. Conventional DCs 
require the transcription factor RelB to enable priming of the immune system through CD40 and  
MHC-molecule expression [20,21]. Blocking of RelB and other NFKB family members in cDCs 
results in induction of Tregs through modified cDC activity, therefore RelB activity is thought to 
determine the outcomes of antigen-presentation to cDCs. Methods to block RelB activity, and that of 
other NFKB family members have been developed to produce modified DCs that are consistently 
tolerogenic through the induction of Tregs [20,22,23]. In murine models of antigen-induced arthritis, 
modified DCs have been shown to suppress joint inflammation and erosion [24]. As tolerance 
induction by these DCs has been shown to be dose-dependent and route-independent [22], after 
induction of inflammatory arthritis by joint injection of methylated bovine serum albumin (mBSA), the 
mice were able to be subcutaneously injected with modified DCs exposed to mBSA, resulting in a 
suppression of inflammatory responses in the joints.  
Given proof of concept studies using regulatory DCs in immunotherapy have demonstrated a 
reduction in effector T cell in other autoimmune diseases [25,26] the use of regulatory DCs as 
autologous immunotherapy is an exciting focus for possible future therapies [10,16,17], particularly in 
the immunomodulation of the inflammation noted in SLE and RA.  
Plasmacytoid dendritic cells (pDCs) constitutively produce anti-viral Type 1 interferons as part of 
the immune response to viral infections. However, in patients with autoimmune diseases, such as SLE, 
pDCs are thought to instead make interferons following TLR ligation by endogenously derived  
nucleic acids [27]. The immune response is, thus, driven not by exogenous infection, but by activity  
against self-antigens.  
Plasmacytoid dendritic cells that produce Type I interferons are found in the tissues of affected 
organs in SLE and other autoimmune conditions. Type I interferons have activity through several 
down-stream pathways to increase dendritic cell maturation and activation and, hence, antigen 
J. Clin. Med. 2015, 4 1198 
 
 
presentation to immune lymphocytes, and non-haematopoietic cell cytokine and MHC expression [6]. 
This immune activation results in up-regulated inflammation, and a positive-feedback loop with  
further dendritic cell production of interferon, and resultant anti-self T cell activation and B cell  
auto-antibody production. 
In patients with active SLE, polymorphonuclear lymphocytes (PMNLs) have been shown to  
up-regulate interferon genes giving an interferon “signature”, which correlates with disease severity, 
and high dose steroids which abrogate this signature induce clinical remission. Depletion of pDCs 
early in the course of SLE can reduce the clinical and serological evidence for autoimmunity [28]. This 
evidence indicates that the ability to model the interactions of pDCs would be beneficial to 
understanding more of the underlying pathogenesis in SLE. 
The routine use of dendritic cells for research into the generation of immunomodulation, or for 
disease modeling in vitro, in SLE, RA and other autoimmune diseases is limited by the lack of 
plentiful and stable dendritic cells of the appropriate phenotype. Peripheral collection of precursors for 
autologous transfer through plasma exchange is not without morbidity, and the cost and logistics for 
wide-spread collection may not be feasible. Therefore, while able to be generated from haematopoietic 
stem cells, regulatory dendritic cells have recently been generated from murine iPSCs [19]. These 
iPSC-derived regulatory dendritic cells have been shown to have similar morphology to bone marrow 
derived regulatory DCs, and appeared to have similar activity to bone marrow derived regulatory DCs 
in not stimulating allogeneic CD4+ T cells, only weakly stimulating allogeneic CD8+ T cells and 
having similar efficient antigen uptake. What remains is to demonstrate stable phenotype and function, 
which can then enable comparison of results in clinical trials and other applications to be explored. 
Once cells are generated from iPSCs, these need to have a valid functional assessment for 
tolerogenic properties. Similarly, as there is a theoretical risk for replication of the disease process with 
autologous transfer of cells, and a demonstrated risk for malignancy with iPSCs, appropriate 
monitoring and assessments will be required. 
3.3. Disease Modelling in SLE or RA 
Theoretically, the potential for disease modelling could be greatly expanded by generating and 
studying the different tissue lineages from patient-derived iPSCs [3]. While neurological tissue 
collection remains elusive, methods for expansion of renal specific cells into iPSCs through  
non-invasive urinary cell collection has been described [29]. Therefore in vitro examination of 
pathological processes using iPSCs derived from affected patients, and, possibly, regeneration of tissue 
from unaffected patients may both be possible. However, the end-organ damage of SLE is a 
manifestation of systemic immune dysregulation therefore the targets of therapy or investigation may 
be more well-focussed on the interactions between cellular populations and an examination of the 
matrix of effects on tolerance and auto-reactivity. Both SLE and RA are multifactorial in their 
pathogenesis with a complex interaction between environment and genetics, resulting in the loss of 
self-tolerance [30,31].  
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4. Generation of Reparative Tissue in Autoimmunity—Diabetes Mellitus 
Diabetes mellitus is a significant clinical problem with high morbidity and mortality associated with 
microvascular and macrovascular complications of hyperglycaemia. Arising either from beta cell 
dysfunction and insulin resistance, or from autoimmune cell-mediated pancreatic islet cell destruction 
and resultant lack of insulin, treatments are usually aimed at glycaemic control, or reducing insulin 
resistance. Accurately and consistently replacing insulin at an amount appropriate for associated oral 
intake can be difficult for patients, with the risk for unstable sugars and hypoglycaemia.  
Replacement of pancreatic tissue through tissue donation is in current use, however limited through 
lack of donors and restrictive through the requirement for life-long immunosuppression. It has been 
previously pointed out therefore, that treatment for diabetes would ideally renew beta cell function 
and, hence, insulin for glycaemic control, prevent repeat autoimmune destruction of the new pancreatic 
tissue, and repair the micro- and macrovascular complications that may have already occurred [32]. 
The current state of play with iPSCs and diabetes, also detailing concerns of immunogenicity, 
tumorigenicity, appropriate differentiation, full maturation, stability of function, and successful engraftment 
have recently been reviewed [33] with much work still required for understanding the basic biology of 
reprogrammed cells.  
However, in terms of current research aspirations, there is great interest in attempting to recapitulate 
normal pancreatic development and generate pancreatic cell types from pluripotent cells [34]. This would 
encompass differentiating iPSCs into definitive endoderm, morphogenesis into a three-dimensional 
structure with contact with appropriate mesenchymal supportive cells to provide required growth and 
development signals, and then commitment of the pancreatic endoderm to endocrine precursor cells and 
thence to beta cells that produce the required insulin in a glucose-responsive fashion.  
Thereafter, considerations need to be made on prevention of rejection of transplants, potentially 
preferring patient-specific iPSC generation and autologous transfer [35]. iPSC lines have so far  
been generated from patients with type 1 and type 2 diabetes, as well as maturity-onset diabetes of the 
young [36–38]. 
In terms of functional beta cell production, polyhormonal insulin-expressing cells have been derived 
from human embryonic stem cells and transplanted for some years now, though whether from 
insufficient cell volume transfer, or transfer of functionally immature beta cells, while helping fasted 
blood glucose states, they do not yet consistently ameliorate diabetes in non-fasted mice subjects, or 
tend to lose insulin-secretion capacity [39–41]. In an alternative line of investigation, when given 
enough time to develop in vivo (90–140 days post transplant), engraftment of pancreatic progenitor 
cells derived from human embryonic stem cells have been able to secrete insulin, and maintain 
normoglycaemia in a murine model of induced diabetes up until the grafts are removed [42]. 
Subsequently, glucose-responsive, insulin-producing cells have been generated from human iPSCs 
and also shown to have the ability in murine models to reverse hypoglycaemia [43], however, can lose 
insulin secretion over time [44]. While it is important to remember that there are differences between 
embryonic stem cells and iPSCs [45], potentially, progenitor pancreatic cells may be developed as  
well from iPSCs for trials in engraftment, but with the advantages inherent over requiring embryonic  
cell sources.  
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5. iPSCs in Autoimmune Neurological Disease—Multiple Sclerosis 
Inducible pluripotent stem cells have been studied extensively in neurodegenerative and 
neurogenetic disorders, more so currently than for inflammatory neurological conditions, such as 
multiple sclerosis (MS), however, the final common pathway of neuronal injury and death is better 
understood in MS than for neurodegenerative conditions. IPSC technology allows potential avenues 
for therapeutics by regeneration of specific neuronal populations [46] or for exerting an 
immunomodulatory effect [47], but also allowing more accurate modelling of neurological disease 
than can be obtained through animal studies [46]. 
MS is the archetypal and most common disabling autoimmune condition of the central nervous 
system (CNS), which provides an ideal framework for research and understanding immune 
dysregulation. MS is a chronic condition, characterised by focal or multifocal inflammatory 
demyelinating episodes resulting in neurological disability depending on the area of the CNS involved. 
There are periods of quiescence and recovery in the most common phenotype, known as remitting 
relapsing MS [48]. 
The pathogenesis of MS and its triggers are multi-factorial with a complex interaction between 
genetic predisposition and environmental factors resulting in immune dysregulation. The first risk 
allele to be identified was the human leukocyte antigen (HLA) class II haplotype HLA-DRB*1501 in 
the 1970s [49]. The Genome-wide Association Study (GWAS) has since identified over 50 
susceptibility loci [50], many of which encode for pro-inflammatory IL-2 and IL-7 [51], with others 
encoding for cytokines, such as CXCR5, IL-12A, IL-12β, and IL-12Rβ1 [48].  
The genetic association alone does not explain fully the development of MS with vitamin D3 and 
Epstein-Barr virus (EBV) both being important environmental factors to consider in MS. Increased 
latitude is associated with lower serum levels of vitamin D3, due to lower levels of sun exposure, 
which corresponds with the higher incidence and prevalence of MS in these high latitude  
countries [48,52] though the effect of vitamin D3 deficiency on adaptive immunity is not yet fully 
understood. What has also been observed, is that individuals who are seronegative for EBV have 
almost no risk of developing MS [53], and it has been hypothesised that, through molecular mimicry, 
EBV may mimic myelin basic protein pathogenic antigens by presentation on HLA-DRB1*1501, 
therefore, providing links to both environmental and genetic risk factors [48,54]. Myelin reactive 
CD4+ T cells secreting interferon gamma are one of many T cell mediators in the pathogenesis of  
MS [55], with the role of other cell types and cell subsets being also involved, with a reduction in 
effector function of Tregs in MS patients [56], and a key role of pro-inflammatory T helper 17 (Th17) 
cells emerging [48,57]. Given the production of oligoclonal bands in CSF, there is a role of B cells in 
MS pathology, and the understanding of the part played by innate immunity by way of NK (natural 
killer) cells and dendritic cells in the pathogenesis is evolving [48].  
Given the significant effects of MS on affected patients, efforts to provide regenerative or 
immunomodulatory therapy are highly sought. 
Oligodendrocyte precursor cells (OPCs) derived from iPSCs, first described by Onorati et al. in  
2010 [58], possibly provide an exogenous way in which to remyelinate axons as soon as possible after 
an episode of acute demyelination, to best protect axons from ongoing inflammation and eventual 
gliosis. Axonal loss is responsible for the most debilitating functional deficits in the more progressed 
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stages of MS, with this loss followed by retrograde neuronal degeneration [59]. Axonal degeneration 
not only occurs in chronic lesions, with good evidence now showing axonal injury in acute  
lesions [60]. 
Cell replacement with OPCs derived from iPSCs have been shown to be successful in animal 
studies, with remyelination and amelioration of disability in experimental autoimmune encephalitis 
(EAE), an animal model of MS [61,62]. 
Neural precursor cells (NPCs) derived from iPSCs have also been shown in EAE to not only have a 
regenerative effect, but also an immunomodulatory effect. One study, in which mouse iPSC-derived 
NPCs were intrathecally transplanted in mice with EAE, exerted a neuroprotective effect, not by 
differentiating into myelin producing cells, but by producing the specific neurotrophin, leukaemia 
inhibitory factor (LIF), which supports the in vivo survival and differentiation of native  
oligodendrocytes [63]. LIF has been shown to inhibit the differentiation of Th17 cells through MAP 
kinase suppression of the cytokine signalling 3 (SOCS3) inhibitory signalling cascade, antagonising 
the interleukin 6 (IL-6)-mediated phosphorylation of signal transducer and activator of transcription 3 
(STAT3) [64], which is essential for the differentiation of Th17 cells, thus limiting CNS inflammation 
and hence subsequent tissue damage.  
Finally, the disease in a dish approach may give unique insights into the study of pathogenesis in 
neuronal disease and in particular to inflammatory diseases of the CNS, given its inaccessibility. IPSCs 
have been successfully derived from a MS patient’s dermal fibroblasts, and differentiated into 
astrocytes, oligodendrocytes and neurons with a normal karyotype. The patient-derived neurons 
showed electrophysiological differences compared with the control cell line, paving the way for a 
novel approach to the study of MS pathogenesis [65]. 
6. Conclusions  
Autoimmune diseases are the result of a combination of environmental influences acting on a 
susceptible genetic background. This causes significant aberrations of self-antigen recognition, 
lymphocyte activation and differentiation, production of pro-inflammatory cytokines and 
autoantibodies, and the final end product of tissue and organ damage. Induced pluripotent stem cells 
technology has the potential to create new safe treatment options, as well as better models to study 
disease and therapies in vitro. Here, we review the so far limited literature in this field. In addition to 
organ replacement strategies where iPSC technology has been applied, we propose that complex  
auto-immune diseases require unique immunomodulatory therapy strategies using cellular components 
and that these components could be made by iPSC technology. Importantly, iPSC technology enables 
us to produce, differentiate and genetically modify large numbers of immune cells that can be used 
therapeutically. Prior to the development of such technologies modification of small cell populations 
with limited ex vivo expansion potential was near impossible. Nevertheless, these novel approaches 
will need to have extensive functional and safety assessments prior to their use in a clinical setting.  
Finally, iPSC technology allows for modelling of normal and diseased (based on genetic and 
epigenetic modifications) cellular growth and development, influences of mutations onto function and 
clinical phenotype. In the time of personalized medicine iPSC technologies are likely to feature as a 
key therapeutic tool in auto-immune diseases. 
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